Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $111.18M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.01M
Average 4.03M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -6.9% | -9.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -6.9% over three years. Forward estimates point to Revenue at -9.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
KalVista Pharmaceuticals, Inc. NASDAQ:KALV | $1.44B | $27.00 | Not rated | -9.9 | +89.21% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | $10.64 | Not rated | -24.1 | +11.88% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | -7.14% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +6.94% |
Olema Pharmaceuticals, Inc. NASDAQ:OLMA | $662.30M | $7.56 | Not rated | -5.1 | -64.15% |
Zevra Therapeutics, Inc. NASDAQ:ZVRA | $540.30M | $9.08 | Overvalued | 6.1 | -3.09% |
Prothena Corporation plc NASDAQ:PRTA | $419.01M | $8.16 | Not rated | -3.1 | -20.27% |
Compass Therapeutics, Inc. NASDAQ:CMPX | $139.35M | $0.77 | Not rated | -5.5 | -87.69% |
Gossamer Bio, Inc. NASDAQ:GOSS | $67.10M | $10.97 | Not rated | -0.2 | +261.97% |
Continue the stock analysis
Jump to another research area for this company.